ATAnu M. Turpeinen

Anu M. Turpeinen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anu M. Turpeinen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is Vitamin D Fortification of Dairy Products Effective for Improving Vitamin D Status? A Systematic Review and Meta-Analysis of Randomised Controlled Trials

    by Cheuk Lun Wong, D. Ian Givens, Anu M. Turpeinen, Xinyue Liu, Jing Guo

    Background/objectives: Given the suboptimal vitamin D intake and status among the United Kingdom population, the Scientific Advisory Committee on Nutrition is seeking suitable food vehicles for vitamin D fortification. Thus, this study aimed to examine the efficacy of vitamin D-fortified dairy products in improving serum 25-hydroxyvitamin D [25(OH)D] concentration using data from randomised controlled trials (RCTs). Methods: PubMed, Embase, and Web of Science were searched from inception until October 2024. Studies were included if they were RCTs with intervention groups administered vitamin D-fortified dairy products and control groups administered unfortified dairy products, as well as examining the effects on serum 25(OH)D concentration. Results: There were 35 RCTs eligible for inclusion, involving 4965 participants (intervention: 2526; control: 2439). The results showed that serum 25(OH)D concentrations were significantly increased by vitamin D3-fortified milk/milk powder (n = 15, mean difference (MD): 18.31 nmol/L, 95% confidence interval (CI): 13.30–23.33 nmol/L, I2 = 95%), vitamin D3-fortified yoghurt/yoghurt drinks (n = 11, MD: 26.22 nmol/L, 95% CI: 18.67–33.77 nmol/L, I2 = 97%), vitamin D2-fortified milk/milk powder (n = 3, MD: 11.61 nmol/L, 95% CI: 9.31–13.91 nmol/L, I2 = 0%), vitamin D-fortified (type not specified) milk/milk powder (n = 8, MD: 13.59 nmol/L, 95% CI: 8.54–18.64, I2 = 98%), and vitamin D-fortified (type not specified) yoghurt/yoghurt drinks (n = 4, MD: 27.74 nmol/L, 95% CI: 16.83–38.64 nmol/L, I2 = 91%), but insignificantly increased by vitamin D3-fortified cheese (n = 5, MD: 16.78 nmol/L, 95% CI: −3.61–37.16, I2 = 99%). However, the results of vitamin D3-fortified cheese became significant when leave-one-out analysis was performed by omitting one RCT (MD: 24.13 nmol/L, 95% CI: 4.69–43.58, I2 = 90%). Conclusions: These findings provide evidence that vitamin D-fortified dairy products have the potential to improve serum 25(OH)D concentrations in populations.


  • Open Access

    Tolerance of protein-hydrolyzed lactose-free A1 milk and A2 milk in lactose-tolerant and lactose-intolerant volunteers: A randomized crossover trial with 2 parallel groups

    by Enni Mannila, Liisa Hokkanen, Eija Ahonen, Anu M. Turpeinen, Marko Kalliomäki, Maaria Kortesniemi, Kaisa M. Linderborg

    Some studies have shown that only A2 β-casein-containing milk (A2 milk) causes fewer gut symptoms in milk-sensitive individuals compared with milk containing both A1 and A2 β-caseins (A1A2 milk). However, in most of the previous clinical studies, the role of lactose in symptom generation has been largely overlooked. Partial hydrolysis of β-caseins during milk processing has been noted to influence gastrointestinal symptoms of sensitive individuals, such as those with irritable bowel syndrome. Currently, there is no clear conclusion about the factors behind gut symptoms in milk-sensitive individuals, aside from lactose in those who are lactose intolerant, or milk protein allergy. Our study involved a 3-leg, 3-d randomized crossover trial examining the effects of heat-treated, homogenized A2 and hydrolyzed A1A2 milk on gastrointestinal symptoms, fecal calprotectin, and plasma inflammation markers in 36 self-reported milk-sensitive volunteers. During the result interpretation phase, the participants were categorized into groups according to their lactase enzyme genotype. There was no difference in the amount of perceived gut symptoms between A2 and A1A2 hydrolyzed milk in the lactose-tolerant group, while gut symptoms increased in the lactose-intolerant group along with the increasing lactose content. Calprotectin and high-sensitivity CRP did not increase during any of the intervention periods compared with the milk-free run-in period. Weak evidence of certain inflammatory cytokine changes was seen, but no significant results were obtained. In conclusion, protein-hydrolyzed lactose-free A1A2 milk was as tolerated as A2 milk in lactose-tolerant volunteers and better tolerated by lactose-intolerant volunteers.